Expression of IL-13 and IL-13Rα1 in Hodgkin lymphomas and non-Hodgkin lymphomas
| Diagnosis . | IL-13+ cases*/ total cases (%) . | IL-13Rα1+ cases*/total cases (%) . |
|---|---|---|
| Classical Hodgkin lymphoma | 31/36 (86%) | 24/27 (89%) |
| Nodular sclerosis | 21/23 (91%) | 16/17 (94%) |
| Mixed cellularity | 8/10 (80%) | 5/7 (71%) |
| Lymphocyte depletion | 2/3 (67%) | 3/3 (100%) |
| Nodular lymphocyte predominance Hodgkin lymphoma | 0/5 | ND |
| Diffuse large B-cell lymphoma | 0/8 | ND |
| T-cell-rich B-cell lymphoma | 1/5 (20%) | ND |
| Anaplastic large-cell lymphoma | 2/5 (40%) | ND |
| Peripheral T-cell lymphoma, unspecified | 1/5 (20%) | ND |
| Diagnosis . | IL-13+ cases*/ total cases (%) . | IL-13Rα1+ cases*/total cases (%) . |
|---|---|---|
| Classical Hodgkin lymphoma | 31/36 (86%) | 24/27 (89%) |
| Nodular sclerosis | 21/23 (91%) | 16/17 (94%) |
| Mixed cellularity | 8/10 (80%) | 5/7 (71%) |
| Lymphocyte depletion | 2/3 (67%) | 3/3 (100%) |
| Nodular lymphocyte predominance Hodgkin lymphoma | 0/5 | ND |
| Diffuse large B-cell lymphoma | 0/8 | ND |
| T-cell-rich B-cell lymphoma | 1/5 (20%) | ND |
| Anaplastic large-cell lymphoma | 2/5 (40%) | ND |
| Peripheral T-cell lymphoma, unspecified | 1/5 (20%) | ND |
Cases with IL-13 or IL-13Rα1 positive malignant cell population (HRS cells in classical HL, L&H cells in NLPHL, and large B-cells in TCRBCL); ND = not done.